12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Phase II data

A Phase II trial in 63 evaluable patients with newly diagnosed DLBCL or grade IIIb follicular lymphoma showed that Revlimid plus R2-CHOP chemotherapy (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) led to an ORR of 98%, including a complete response rate of 74%. The 18-month PFS rate was 66%. Additionally, a subgroup analysis showed that the PFS rate was not significantly different between patients with germinal center B cell (GCB) subtype DLBCL and non-GBC subtype...

Read the full 347 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >